PONESIMOD

S1P Receptor Modulator

Brand names: PONVORY, Ponvory

Oral

Mechanism of Action

12.1 Mechanism of Action Ponesimod is a S1P receptor 1 modulator that binds with high affinity to S1P receptor 1. Ponesimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which ponesimod exerts therapeutic effects in MS is unknown, but may involve reduction of lymphocyte migration into the central nervous system.

Indications

1 INDICATIONS AND USAGE PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

relapsing-remitting disease

and active secondary progressive disease

in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS)

to include clinically isolated syndrome

Contraindications

• 4 CONTRAINDICATIONS PONVORY is contraindicated in patients who: In the last 6 months
• have experienced myocardial infarction
• unstable angina
• stroke
• transient ischemic attack (TIA)

FDA Warnings

5 WARNINGS AND PRECAUTIONS Infections : PONVORY may increase the risk of infections
6 ) Fetal Risk : Women of childbearing potential should use effective contraception during and for 1 week after stopping PONVORY
7 ) Macular Edema : Increases the risk of macular edema
Diabetes mellitus and uveitis increase the risk

Known Side Effects

7 documented side effects by frequency

Fatigue

>10%

Dizziness

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Drug Not Working

1-10%

Nausea

0.1-1%

Drowsiness

0.1-1%

Community Discussions

No community discussions found for PONESIMOD yet.

Compare With

9 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral